Navigation Links
ViroPharma Shares Fall As FDA Moves Towards Generic Vancocin

Speculation that the Food and Drug Administration will give a nod for the generic version of Vancocin caused shares in ViroPharma to dip by about 33 percent. The rumors of the FDA's changed perspective // strengthened after Laura Alvey, a spokeswoman for the F.D.A said in an e-mail message that the agency had "recently revised the bioequivalence recommendations for oral vancomycin from a clinical trial with bioequivalence endpoints to an in vitro method involving dissolution testing."

Vancocin or vancomycin is used exclusively to treat hospital-acquired bacterial infections caused in the lower digestive tract by the bacterium Clostridium difficile. Basically, the FDA's changed stance means that a clinical trial for generic vancomycin might not be necessary if it dissolves at the same rate as Vancocin. ViroPharma has intimated that it has filed a petition to stay the action with the F.D.A and added that it would file many more petitions to support "vigorous opposition to any approach that does not require rigorous scientific methods to demonstrate a rate and extent of drug release to the site of action consistent with good medicine and science." But analysts at Infinium Capital feel that a generic version of Vancocin could be available by early 2008. "Previously, generic manufacturers may not have been interested in developing this therapeutic due to its low revenue potential; however, with the recent sales growth of 133 percent in 2005, Vancocin is now on the radar screen," an analyst at Infinium Capital, Bernadine Leung, said.
'"/>




Page: 1

Related medicine news :

1. Shares Of AVI BioPharma Drops On Reports Of Disappointing Early Drug Trail
2. Sun Pharma Allots Shares Upon Fccbs Conversion
3. Zenotech Issues 20 Lakh Shares to Ranbaxy for Rs 20 Cr
4. FDA Moves In To Check Listeria
5. Genetic Test for Type II Diabetes Moves Closer
6. Inhaled Insulin Study Moves Ahead
7. Looking Towards More Effective Leukemia Treatment
8. Attitude Towards AIDS Patients – Time For A Change
9. Scientists Awarded Appropriately For Contribution Towards Medical Research
10. A Step Towards Unraveling The Schizophrenia And Depression Mystery
11. Are Women Not Hearty Enough Towards Seeking Heart Care?
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: